^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Peritoneal Cancer

    1d
    Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P1, N=31, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Jun 2026 | Trial primary completion date: Dec 2026 --> Jun 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    Zejula (niraparib) • Aliqopa (copanlisib)
    2d
    Diffuse peritoneal mesothelioma presenting with the appearance of mesenteric panniculitis: A case report. (PubMed, Oncol Lett)
    A total of six cycles of pemetrexed-cisplatin chemotherapy were given and elicited a partial response. The disease progressed and intraperitoneal bevacizumab-cisplatin therapy was administered, which was ineffective...Correct diagnosis is facilitated by an awareness of occupational exposure risk, such as that of asphalt exposure for the present case, and early histopathological evaluation. The prognosis for DPM remains poor despite multimodal therapy, and novel therapeutic strategies are needed.
    Journal
    |
    WT1 (WT1 Transcription Factor)
    |
    Avastin (bevacizumab) • cisplatin • pemetrexed
    5d
    ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=33, Recruiting, Alexander B Olawaiye, MD | Trial completion date: Mar 2033 --> Dec 2034 | Trial primary completion date: Dec 2031 --> Nov 2033
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    Talzenna (talazoparib) • ZEN-3694
    5d
    Nationwide survey of hereditary breast and ovarian cancer-related clinical practice in gynecologic oncology in Japan: a joint study by the Japan Society of Gynecologic Oncology (JSGO) and the Japan Society of Obstetrics and Gynecology (JSOG). (PubMed, J Gynecol Oncol)
    Although HBOC-related genetic testing and preventive strategies are widely implemented in Japan, this nationwide survey revealed critical structural and evidence gaps, particularly in institutional capacity and the management of evidence-limited scenarios such as STIC, underscoring the need for system-level improvement.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    Myriad myChoice® CDx
    6d
    TIPC: TLR9 Immunotherapy for Peritoneal Carcinomatosis (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Brown University
    New P1 trial
    6d
    Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=48, Recruiting, Ronald Buckanovich | Trial completion date: Mar 2033 --> Sep 2032 | Trial primary completion date: Mar 2031 --> Aug 2031
    Trial completion date • Trial primary completion date • Platinum resistant
    |
    BRCA (Breast cancer early onset) • CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • Erivedge (vismodegib)
    7d
    TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE) (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, Case Comprehensive Cancer Center
    New trial
    7d
    Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) (clinicaltrials.gov)
    P2/3, N=175, Recruiting, GE Healthcare | Initiation date: May 2026 --> Oct 2026
    Trial initiation date
    9d
    mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian (clinicaltrials.gov)
    P1, N=159, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Truqap (capivasertib) • vistusertib (AZD2014)
    12d
    CX3CR1-Dependent Macrophages Drive Ovarian Cancer Progression Through MMP-2 and TGF-β Production. (PubMed, Cancers (Basel))
    The CX3CL1-CX3CR1 axis promotes ovarian cancer progression by recruiting MMP-2- and TGF-β-producing macrophages. Targeting CX3CR1-dependent TAM functions may represent a therapeutic strategy for limiting peritoneal dissemination in ovarian cancer.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2) • TGFB1 (Transforming Growth Factor Beta 1) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
    12d
    Development of a prognostic model for postoperative survival in appendiceal pseudomyxoma peritonei based on clinical indicators. (PubMed, World J Surg Oncol)
    Histological type, preoperative PCI, CA125, LINS, and CC score are independent prognostic factors in appendiceal PMP. The developed nomogram offers accurate survival predictions and can be updated with new data for improved clinical decision-making.
    Retrospective data • Journal
    |
    LINS1 (Lines Homolog 1)
    12d
    Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study. (PubMed, Gynecol Oncol)
    NACT with atezolizumab was feasible and did not delay ICS. Translational parameters showed heterogeneous changes reflecting both immune activation and adaptive immune resistance.
    Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL10 (Interleukin 10)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • paclitaxel